Skip to main content
. Author manuscript; available in PMC: 2011 Aug 9.
Published in final edited form as: Cancer Cell. 2010 Aug 9;18(2):160–170. doi: 10.1016/j.ccr.2010.06.014

Figure 5. Administration of chemotherapeutics after antibody treatment enhances primary tumor reduction but reduces immunity induced by anti-neu antibody.

Figure 5

WT BALB/c mice (n=5–10/group) were injected s.c. with 5 × 105 TUBO cells and treated with 100 μg of anti-neu antibody (α-neu) on days 11 and 16. Select chemotherapeutic agents were injected i.p. at different time points. One of three experiments is shown. (A) 100 mg/kg of Cyclophosphamide (CTX) was injected i.p. on days 16, 23, and 33. (B) 40 mg/kg of Paclitaxel (PTX) weas injected i.p. on days 14 and 19. Treated, tumor-free mice were re-challenged with 2 × 106 TUBO cells when primary tumor was not detected for at least 30 days. Percent tumor-bearing mice (C) and mean tumor volume (D) are shown. Reduced T cell proliferation was seen in Figure S3.